Divalproex Sodium Delayed-release Tablets USP — Class III drug recall D-1449-2016
Terminated recall by Teva North America, reported 2016-08-03, distributed nationwide. Failed Tablet/Capsule Specifications
| Recall number | D-1449-2016 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva North America, Horsham, PA, United States |
| Recall initiated | 2016-05-18 |
| Classified | 2016-07-27 |
| Reported by FDA | 2016-08-03 |
| Terminated | 2017-01-17 |
| Distributed | Nationwide (US) |
| NDC | 00093-7440-01 |
| Lot numbers | 02D163 |
| Expiration dates | 2017-09 |
Product
Divalproex Sodium Delayed-release Tablets USP, RX, 250 mg, 100 count bottles, Manufactured in Israel by: TEVA PHARMACEUTICALS IND. LTD. Jerusalem, 9777402, Israel, Manufactured for: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454, NDC 0093-7440-01.
Reason for recall
Failed Tablet/Capsule Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1449-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.